The stock of Amphastar Pharmaceuticals Inc (AMPH) has seen a -2.73% decrease in the past week, with a 2.22% gain in the past month, and a -9.05% decrease in the past quarter. The volatility ratio for the week is 1.25%, and the volatility levels for the past 30 days are at 2.03% for AMPH. The simple moving average for the past 20 days is -1.11% for AMPH’s stock, with a -29.71% simple moving average for the past 200 days.
Is It Worth Investing in Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) Right Now?
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has a price-to-earnings ratio of 9.20x that is above its average ratio. Additionally, the 36-month beta value for AMPH is 0.76. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for AMPH is 34.78M and currently, short sellers hold a 11.78% ratio of that float. The average trading volume of AMPH on June 19, 2025 was 580.84K shares.
AMPH) stock’s latest price update
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has experienced a decline in its stock price by -1.05 compared to its previous closing price of 25.61. However, the company has seen a fall of -2.73% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-22 that RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar’s Pharmaceuticals website at http://ir.amphastar.com.
Analysts’ Opinion of AMPH
Many brokerage firms have already submitted their reports for AMPH stocks, with JP Morgan repeating the rating for AMPH by listing it as a “Neutral.” The predicted price for AMPH in the upcoming period, according to JP Morgan is $30 based on the research report published on May 12, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see AMPH reach a price target of $36, previously predicting the price at $66. The rating they have provided for AMPH stocks is “Neutral” according to the report published on February 04th, 2025.
Wells Fargo gave a rating of “Equal Weight” to AMPH, setting the target price at $55 in the report published on November 22nd of the previous year.
AMPH Trading at 2.42% from the 50-Day Moving Average
After a stumble in the market that brought AMPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.03% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMPH starting from Petersen Floyd F., who sale 500 shares at the price of $25.67 back on Jun 02 ’25. After this action, Petersen Floyd F. now owns 72,909 shares of Amphastar Pharmaceuticals Inc, valued at $12,835 using the latest closing price.
Petersen Floyd F., the Director of Amphastar Pharmaceuticals Inc, proposed sale 500 shares at $25.61 during a trade that took place back on Jun 02 ’25, which means that Petersen Floyd F. is holding shares at $12,805 based on the most recent closing price.
Stock Fundamentals for AMPH
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.5 for the gross margin
The net margin for Amphastar Pharmaceuticals Inc stands at 0.19. The total capital return value is set at 0.14. Equity return is now at value 19.90, with 8.85 for asset returns.
Based on Amphastar Pharmaceuticals Inc (AMPH), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is 6.95.
Currently, EBITDA for the company is 277.31 million with net debt to EBITDA at 1.84. When we switch over and look at the enterprise to sales, we see a ratio of 2.29. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In conclusion, Amphastar Pharmaceuticals Inc (AMPH) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
